CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Other Events
Item 8.01
| Other Events. |
On April 4, 2017, Corvus Pharmaceuticals, Inc. (Corvus or the
Company) issued a press release announcing interim safety and
efficacy results from its ongoing Phase 1/1b study demonstrating
safety and clinical activity of lead checkpoint inhibitor CPI-444
in patients with advanced cancers. The full text of the press
release is filed as Exhibit 99.1 hereto and is incorporated
herein by reference.
| Item 7.01 | Regulation FD Disclosure. |
On April 4, 2017, the interim data discussed above was presented
in an oral plenary session at the American Association for Cancer
Research (AACR) Annual Meeting 2017 in Washington, D.C., by
Leisha Ann Emens, M.D., Ph.D., study investigator and associate
professor of oncology at Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center. A copy of the presentation,
including a slide setting forth certain cautionary language
intended to qualify the forward-looking statements included in
the presentation, is furnished as Exhibit 99.2 to this Current
Report and is incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form
8-K shall not be deemed filed for purposes of Section 18 of the
Securities Act of 1934, as amended (the Exchange Act), or
otherwise subject to the liabilities of that Section, or
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
Reference is made to the Exhibit Index attached hereto.
About CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue. CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Recent Trading Information
CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) closed its last trading session down -11.75 at 8.96 with 104,239 shares trading hands.
